Virbac stock gains after strong H1 2026 results and confirmed outlook

Virbac stock (ISIN FR0000031577) advanced on Euronext Paris on September 17, 2026 after the French animal health group reported strong half-year 2026 results, including revenue of EUR 768.0 million and an adjusted EBIT margin of 18.8 percent, while confirming its full-year guidance at the upper end of the range.

Half-year 2026 figures show solid growth

According to Zonebourse, Virbac generated consolidated revenue of EUR 768.0 million in the first half of 2026, representing organic growth of 7.4 percent at constant exchange rates and scope compared with the first half of 2025, while reported growth at actual exchange rates was 4.0 percent.

The same half-year report shows that adjusted recurring operating income before amortization of acquisition-related assets (adjusted EBIT) rose to EUR 144.2 million in H1 2026 from EUR 135.0 million in H1 2025, an increase of 6.8 percent that lifted the adjusted EBIT margin to 18.8 percent from 18.3 percent a year earlier.Zonebourse

Consolidated net income for H1 2026 increased by 5.9 percent to EUR 87.1 million compared with EUR 82.2 million in the prior-year period, while net debt stood at EUR 196 million at June 30, 2026 versus EUR 173 million at December 31, 2025, reflecting typical working capital seasonality.Zonebourse

Supercharge platforms and guidance at upper end

Virbac highlighted that growth was driven by both major segments, with companion animal revenue up 10.0 percent and farm animal revenue up 6.7 percent at constant exchange rates and scope in H1 2026, supported by a strong contribution from its Supercharge platforms (excluding Thyronorm), which increased by around 12 percent at constant exchange rates and scope.PR Newswire

As PR Newswire reported on September 17, 2026, the company confirmed its 2026 guidance and stated that the strong first-half performance positions it to target the upper end of its initial revenue growth range of 5.5 percent to 7.5 percent at constant exchange rates and scope, with an adjusted recurring operating income margin expected around 17 percent at constant exchange rates and scope for the full year.

The half-year data also show that operating cash flow before interest and taxes reached EUR 173.0 million in H1 2026, significantly exceeding capital expenditures of EUR 57.3 million, underscoring Virbac's capacity to fund investment while maintaining disciplined balance sheet management.ScanX News

Stock reaction on Euronext Paris

Per price data from a French stock portal, Virbac stock closed at EUR 312.00 on Euronext Paris on September 16, 2026, before releasing its H1 2026 results, and then traded at around EUR 314.50 at 17:35 on September 17, 2026, implying a day-on-day gain of roughly 0.8 percent and leaving the shares modestly above the prior closing level.

At the closing price of EUR 312.00 on September 16, 2026, a previous report estimated Virbac's market capitalization at about EUR 3.05 billion, illustrating its position as a mid-cap player in the European animal health and consumer goods space.Ad-hoc-news

A market overview on a French financial site listed Virbac among the stocks to watch in Paris on September 17, 2026, noting that the company was due to publish its financial results after the market close, a timing that helped make the latest H1 figures a direct catalyst for Virbac stock on that date.Boursorama

Key data for Virbac stock

Based on recent Euronext Paris data, Virbac stock traded under the ticker VIRB, with the closing price of EUR 314.50 on September 17, 2026 sitting slightly above the previous day's EUR 312.00 level and within a typical range for the shares over the preceding sessions, while the company's market capitalization at recent levels remained in the vicinity of EUR 3.0 billion in euro terms.

More news and analyses on Virbac stock